News | Oncology Related Products | March 31, 2016

The History and Future of Cancer Immunotherapy

Imaging will continue to be used for response assessment as new therapies continue to develop

cancer immunotherapy, development, Axel Hoos, Nature Reviews, imaging

March 31, 2016 — In a paper published in Nature Reviews last week, Axel Hoos, M.D., Ph.D., laid out the current immunotherapy development paradigm, as well as his strategic vision to optimize the implementation of next-generation immunotherapies.

Immunotherapy is currently revolutionizing cancer treatment and, according to Axel Hoos, M.D., Ph.D., has the potential to improve patient outcomes significantly in the future. Hoos leads one of the Cancer Research Institute’s (CRI) programs — the Cancer Immunotherapy Consortium (CIC) — that played an important role in enabling early immunotherapy trials to succeed.

Imaging is often used to monitor patient response to this therapy, but there is difficulty in measuring treatment response because it presents very differently than traditional chemotherapy response. The tumors sometimes increase in size for a couple of months before the treatment begins to shrink tumors over time. The tumor tissue response is also often delayed and may be mistaken as ineffective in the first couple months of monitoring.

Under the leadership of Hoos, who also serves as GlaxoSmithKline’s head of immuno-oncology, the CIC initiatives highlighted how two important factors were complicating immunotherapy trials. First, immunotherapy can produce novel responses that are not accounted for in the traditional response criteria developed for chemotherapy. Second, immunotherapy’s differential effects on clinical endpoints, such as survival, need to be addressed. In addition to the development of new immune-related response criteria (irRC), Hoos also believes that the CIC’s insights helped to transform the development program for the first checkpoint blockade immunotherapy drug, the anti-CTLA-4 antibody ipilimumab (Yervoy), which unleashes the immune system and enables a stronger anti-cancer response.

With the help of the new immunotherapy-related criteria, early trials employing ipilimumab as well as other checkpoint blockade drugs, such as the anti-PD-1 antibody pembrolizumab (Keytruda) and nivolumab (Opdivo), paved the way for immunotherapy to improve the standard of care in cancer treatment. Furthermore, these stimulated cooperative efforts in the immunotherapy community that directly influenced the regulatory guidance documents of both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Moving forward, Hoos hopes that the CIC, which has since been reconstituted as an industry advisory “think tank” focused on late-stage drug development, can build on these accomplishments. According to him, several factors will drive the efforts to usher in the next generation of immunotherapies — including technologies such as cancer vaccines, re-engineered oncolytic viruses and cell-based therapies — as well as to maximize the benefits of current immune-based drugs:

  • First, immunotherapy has already started to change the standard of care in oncology, both in significant improvements in survival as well as side effects. This will substantially change the treatment landscape and will require careful integration of immunotherapies into current treatment strategies as new information becomes available;
  • Second, there is still room to improve the criteria by which clinicians can determine successful patient responses to immunotherapy;
  • Third, not all patients respond to the same treatment the same way. To ensure each patient receives the most beneficial treatment for their particular tumors, better immune biomarkers must be developed;
  • Fourth, while individual immunotherapies have already produced clinical improvements, early trials with combination therapies suggest that benefits can be improved. Determining rational strategies for combination therapies will be a high priority moving forward; and
  • Fifth, novel immunotherapy technologies already present much promise, and by incorporating recent scientific breakthroughs into the design of treatments, their effectiveness will continue to improve patient outcomes in the future.

Immunotherapy was declared the Breakthrough of the Year by Science in 2013. To ensure that immunotherapy realizes its full potential, much more must be learned about the immune system, cancer, and their interactions within the complex and ever-changing tumor environments of individual patients.

For more information: www.nature.com/reviews

Related Content

A new study published in Radiology: Cardiothoracic Imaging on cardiac imaging trends over a decade reports that the rate of coronary computed tomography angiography (cCTA) exams by radiologists in hospital outpatient departments increased markedly from 2010 to 2019, suggesting a bright future for the technology.

Getty Images

News | Cardiac Imaging | September 28, 2021
September 28, 2021 — A new study published in ...
September 28, 2021 — A computer program trained to see patterns among thousands of breast ultrasound images can aid physicians in accurately diagnosing breast cancer, a new study shows.

Breast ultrasound images show cancer (at left, as dark spot in center and, at right, in red, as highlighted by a computer). Image courtesy of Nature Communications

News | Breast Imaging | September 28, 2021
September 28, 2021 — A computer program trained to see patterns among thousands of...
GE Healthcare's Definium Tempo Fixed X-ray System (Photo: Business Wire)

GE Healthcare's Definium Tempo Fixed X-ray System (Photo: Business Wire)

News | Digital Radiography (DR) | September 28, 2021
September 28, 2021 — GE Healthcare introduced the Definium Tempo, a new fixed, overhead tube suspension (OTS)...
GE Healthcare unveiled Revolution Ascend with Effortless Workflow, offering clinicians a collection of artificial intelligence technologies that automate and simplify time-consuming tasks to increase operational efficiency and free up time for clinicians to deliver more personalized care to more patients.
News | Computed Tomography (CT) | September 27, 2021
September 27, 2021 — GE Heal
Esaote, an Italian company leader in the biomedical equipment sector – ultrasound, MRI and software for the medical sector – launched E-shop: the new online store to reach medical professionals more quickly and effectively.
News | Radiology Business | September 27, 2021
September 27, 2021 — Esaote, an Italian company leader in the biomedical equipment sector –...

Image courtesy of Ziehm

News | Mobile C-Arms | September 27, 2021
September 27, 2021 — According to the statistics by the World Health O...
Doctors say they should be making medical decisions with patients, not insurance carriers and outline principles for noninvasive testing
News | Cardiac Imaging | September 23, 2021
September 22, 2021 — Test selection should be a shared decision between patient and physician rather than directed by
GE has entered into an agreement to acquire BK Medical, a leader in advanced surgical visualization, from Altaris Capital Partners for a cash purchase price of $1.45 billion.

Getty Images

News | Radiology Business | September 23, 2021
September 23, 2021 — GE has entered into an
This study shows that thanks to deep learning analysis applied to digitized pathology slides, artificial intelligence can classify patients with localized breast cancer between high risk and low risk of metastatic relapse in the next five years.

Getty Images

News | Artificial Intelligence | September 22, 2021
September 22, 2021 — The RACE AI study conducted by Gustave...